Leading healthcare product maker Covidien plc (COV) will present new data on its laparoscopic surgical products at the ongoing annual meeting of the Society of American Gastrointestinal and Endoscopic Surgeons (“SAGES 2011”) in San Antonio, Texas.
The Ireland-based company will showcase its surgical products and present data from self-sponsored clinical studies at SAGES 2011 on April 1 and April 2, 2011, in two podium presentations, two video sessions as well as eight poster presentations. Moreover, Covidien will exhibit the latest advancements in general, bariatric and colorectal surgical instrumentation.
Surgeons attending the meeting will have an opportunity to gain hands-on experience and training in advanced laparoscopic surgery (through single incision) in a replicated lab environment. This will be enabled by the “Covidien Innovation Tour” training program that covers single incision techniques with the company’s SILS product line and other surgical tools for minimally-invasive procedures. SILS procedures are one of the most significant advancements in laparoscopic surgery over the past two decades.
Products to be featured at SAGES 2011 will include the SILS Port and SILS Hand Instruments for laparoscopic surgery, the Endo GIA surgical stapling system with the Tri-Staple technology, the iDrive stapling platform, the V-Loc wound closure device and the AbsorbaTack absorbable fixation device for laparoscopic abdominal wall surgeries and hernia repair.
Covidien is a leading global healthcare products company that develops and markets medical solutions for better patient outcomes. The company boasts of a well diversified product and technology portfolio.
Covidien remains committed to rolling out new products and technologies, and focused on fast-growing markets and boosting market share in core segments through investments in sales and marketing infrastructure.
Revenues from the company’s endomechanical products (includes laparoscopic instruments and stapling) increased 4% in the last reported quarter driven by strong growth in stapling products. However, laparoscopic instrument sales were flat due to competition. Covidien’s core medical devices business faces stiff competition from Johnson & Johnson (JNJ), Becton Dickinson (BDX) and C.R. Bard (BCR).
BARD C R INC (BCR): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
Zacks Investment Research
